Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 23Paclitaxel 19Epirubicin 14Doxorubicin 13Carboplatin 13Trastuzumab 12Docetaxel 10Taxes 9Albumin-Bound Paclitaxel 7pembrolizumab 5Radiotherapy 5Fluorouracil 5Filgrastim 5Bevacizumab 5130-nm albumin-bound paclitaxel 5pertuzumab 4Neoadjuvant Therapy 4Cisplatin 4eribulin 3Thiotepa 3Tamoxifen 3Panitumumab 3Melphalan 3Magnetic Resonance Spectroscopy 3Flow Cytometry 3Capecitabine 3Biopsy 3sargramostim 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Inflammatory Breast Neoplasms × onvansertib × Clear all
NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡